Akcea Therapeutics, Inc. Stock News

Ionis Pharmaceuticals Inc (NASDAQ: IONS) said it expanded its distribution agreement with Swedish Orphan Biovitrum AB (“Sobi”) for Tegsedi in North America. Tegsedi is indicated for polyneuropat

Akcea merged back into Ionis. Ionis has commercial revenues and an immense clinical pipeline.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Analysts at William Blair dropped their Q3 2020 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research note issued to investor

Akcea Therapeutics Inc (NASDAQ:AKCA) major shareholder Ionis Pharmaceuticals Inc acquired 21,237,715 shares of the stock in a transaction that occurred on Saturday, October 10th. The shares were bough

Advisor Group Holdings Inc. lifted its position in shares of Akcea Therapeutics Inc (NASDAQ:AKCA) by 100.0% during the second quarter, according to the company in its most recent disclosure with the S

In a report released today, Chad Messer from Needham assigned a Buy rating to Ionis Pharmaceuticals (IONS – Research Report),

Akcea Therapeutics Inc (NASDAQ:AKCA) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 1,170,000 shares, a drop o

Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, September 21st. The shares were sold at an average price

American International Group Inc. cut its holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 9.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchan

Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Ex

Bank of America Corp DE cut its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 0.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchan

Vanguard Group Inc. lifted its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Com

Halper Sadeh LLP, a global investor rights law firm, is investigating: Rosetta Stone Inc. (NYSE: RST) concerning potential violations of the federal s

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

The